| Title | Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment |
| Authors | Luo, Jian-Quan Wang, Lu-Yan He, Fa-Zhong Sun, Ning-Ling Tang, Gen-Fu Wen, Jia-Gen Luo, Zhi-Ying Liu, Zhao-Qian Zhou, Hong-Hao Chen, Xiao-Ping Zhang, Wei |
| Affiliation | Cent S Univ, Pharmacogenet Res Inst, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China. Peking Univ, Peoples Hosp, Dept Cardiol, Beijing 100044, Peoples R China. Anhui Med Univ, Sch Hlth Adm, Hefei 230032, Peoples R China. |
| Keywords | antihypertensive response enalapril NR3C2 single nucleotide polymorphism SNP CORONARY-ARTERY-DISEASE MINERALOCORTICOID RECEPTOR MUTATIONS CONVERTING ENZYME-INHIBITORS PSEUDOHYPOALDOSTERONISM TYPE-1 MYOCARDIAL-INFARCTION HYPERTENSION ASSOCIATION PERINDOPRIL EXPRESSION THERAPY |
| Issue Date | 2014 |
| Publisher | pharmacogenomics |
| Citation | PHARMACOGENOMICS.2014,15,(2),201-208. |
| Abstract | Aim: The mineralocorticoid receptor (MR; also known as NR3C2) plays important roles in the modulation of blood pressure. The effect of NR3C2 polymorphisms on antihypertensive response to enalapril was investigated. Patients & methods: Two hundred and seventy nine essential hypertension patients treated with enalapril were genotyped for two NR3C2 tagSNPs, rs5522 and rs2070950, by Sequenom MassArray technology. Results: The reductions in diastolic blood pressure (DBP) were significantly greater in AA homozygotes compared with AG+GG genotype carriers for the rs5522 polymorphism (p = 0.009), and the reductions in DBP were greater in GG homozygotes compared with GC+CC genotype carriers for the rs2070950 polymorphism, with marginal significance (p = 0.065). Stepwise multiple regression analysis indicated that significant predictors of DBP reduction were baseline DBP (p < 0.001), waist:hip ratio (p = 0.001) and rs5522 genotype (p = 0.003). Conclusion:NR3C2 rs5522 affects blood pressure response to enalapril treatment and may serve as a useful pharmacogenomic marker of antihypertensive response to enalapril in essential hypertension patients. Original submitted 8 August 2013; Revision submitted 29 August 2013; Published online 23 September 2013 |
| URI | http://hdl.handle.net/20.500.11897/390060 |
| ISSN | 1462-2416 |
| DOI | 10.2217/pgs.13.173 |
| Indexed | SCI(E) |
| Appears in Collections: | 人民医院 |
